Clinical Trials Directory

Trials / Completed

CompletedNCT04461509

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
62 (actual)
Sponsor
Alessandro D'Agnolo · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.

Detailed description

This is a prospective trial to evaluate the effectiveness of 18F-PSMA PET-hrMRI versus standard mpMRI at identifying prostate cancer targets for HIFU therapy. Participants with clinically localized, unilateral high grade prostate cancer (Gleason score 7-10 prostate cancer localized to one lobe on prior biopsies) OR at high risk for having unrecognized high grade prostate cancer (overall Gleason score 6 with \> half of systematic biopsy cores positive and \> 50% of core involvement in at least one core), interested in HIFU would receive both a standard mpMRI and 18F-PSMA PET-hrMRI. Participants would then undergo a mapping biopsy using a standard sextant template plus MRI/US-fusion targeted biopsy of any lesion suspicious lesion on mpMRI or PET-hrMRI.

Conditions

Interventions

TypeNameDescription
DRUG18F-PSMAImaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA) Other Names: 18F-DCFPyL Injection prostate-cancer-specific radiotracer

Timeline

Start date
2021-04-06
Primary completion
2024-09-03
Completion
2024-09-03
First posted
2020-07-08
Last updated
2026-03-25
Results posted
2025-05-29

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04461509. Inclusion in this directory is not an endorsement.